

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6055337

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	ASTRAZENECA UK LIMITED	01/29/2020
RECEIVING PARTY DATA		
Name:	ASTRAZENECA AB	
Street Address:	SE-151 85	
City:	SODERTALJE	
State/Country:	SWEDEN	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Patent Number:	10407446
CORRESPONDENCE DATA		
Fax Number:	(301)398-9306	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	3013980000	
Email:	patents@astrazeneca.com	
Correspondent Name:	ASTRAZENECA	
Address Line 1:	ONE MEDIMMUNE WAY	
Address Line 4:	GAITHERSBURG, MARYLAND 20878	
ATTORNEY DOCKET NUMBER:	200585-US-NP	
NAME OF SUBMITTER:	KORTNI L. HAYES	
SIGNATURE:	/Kortni L. Hayes/	
DATE SIGNED:	04/10/2020	
Total Attachments: 4		
source=200585-US-NP - executed assignment (AZUK-AZAB)#page1.tif		
source=200585-US-NP - executed assignment (AZUK-AZAB)#page2.tif		
source=200585-US-NP - executed assignment (AZUK-AZAB)#page3.tif		
source=200585-US-NP - executed assignment (AZUK-AZAB)#page4.tif		

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 8th December 2019 (the "Effective Date") by and between

ASTRAZENECA UK LIMITED, a company incorporated in England and Wales under no. 3674842, with registered office address at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, England, CB2 0AA ("Assignor"); and

ASTRAZENECA AB, a company incorporated in Sweden under no. 556011-7482 with registered office address at SE-151 85 Södertälje, Sweden ("Assignee").

WHEREAS, Assignor has agreed to assign to Assignee the Assignor's legal right, legal title and legal interest in and to the patent applications identified in the attached Schedule (the "Applications") and in and to the inventions and improvements disclosed in such Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:


1. For good and valuable consideration made by Assignee to Assignor, receipt of which is hereby acknowledged, the Assignor hereby assigns, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely all their legal right, legal title and legal interest in and to the inventions, the Applications and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Applications and any patents or applications derived therefrom; and the right to file patent applications derived from the Applications directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the "Rights"), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignor acknowledges that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignor waives any right of first refusal that they may have for acquiring such Rights.
2. Assignor agrees with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignor agrees with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.
4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the courts of England and Wales.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.


Signed for and on behalf of
ASTRAZENECA UK LIMITED
Name: MARK NESS
Title: Authorised Signatory


Signed for and on behalf of
ASTRAZENECA AB
Name: ANDREW COOK
Title: Authorised Signatory


Witnessed by DENISE ADAMS
Date: 29/01/2020


Witnessed by DENISE ADAMS
Date: 29/01/2020

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Filing Type	Application Number/Patent Number	Filing Date
200585-AE-PCT	AE	PCT	P6000837/19	19 Dec 2017
200585-AP-AFT	AP	AFT	AP/P/2019/011650	19 Dec 2017
200585-AR-NP	AR	NP	20170103582	19 Dec 2017
200585-AU-PCT	AU	PCT	2017384388	19 Dec 2017
200585-BB-PCT	BB	PCT	2001/1950	19 Dec 2017
200585-BN-PCT	BN	PCT	BN/N/2019/0081	19 Dec 2017
200585-BO-NP	BO	NP	SP281-2017	19 Dec 2017
200585-BR-PCT	BR	PCT	BR112019012217-6	19 Dec 2017
200585-BS-NP	BS	NP	2851	13 Jun 2018
200585-CA-PCT	CA	PCT	3046339	19 Dec 2017
200585-CL-PCT	CL	PCT	201901714	19 Dec 2017
200585-CN-PCT	CN	PCT	201780078065.X	19 Dec 2017
200585-CO-PCT	CO	PCT	NC2019/0007810	19 Dec 2017
200585-CR-PCT	CR	PCT	2019-000301	19 Dec 2017
200585-DO-PCT	DO	PCT	P2019-0168	19 Dec 2017
200585-DZ-PCT	DZ	PCT	190331	19 Dec 2017
200585-EA-EAT	EA	EAT	201991399	19 Dec 2017
200585-EC-PCT	EC	PCT	2019-44159	19 Dec 2017
200585-EG-PCT	EG	PCT	887/2019	19 Dec 2017
200585-EP-EPT	EP	EPT	17825829.9	19 Dec 2017
200585-ET-NP	ET	NP	ET/P/2017/401	19 Dec 2017
200585-GC-GCP	GC	GCP	34464	19 Dec 2017
200585-GT-PCT	GT	PCT	2019-000129	19 Dec 2017
200585-HN-PCT	HN	PCT	2019-001674	19 Dec 2017
200585-ID-PCT	ID	PCT	P00201905862	19 Dec 2017
200585-IL-PCT	IL	PCT	267158	19 Dec 2017
200585-IN-PCT	IN	PCT	201917025114	19 Dec 2017
200585-JM-NP	JM	NP	18/1/5857	19 Dec 2017

200585-JO-PCT	JO	PCT	PCT/2019/151	19 Dec 2017
200585-JP-PCT	JP	PCT	2019-533052	19 Dec 2017
200585-KR-PCT	KR	PCT	10-2019-7021026	19 Dec 2017
200585-LB-NP	LB	NP	11315	19 Dec 2017
200585-MX-PCT	MX	PCT	MX/a/2019/007189	19 Dec 2017
200585-MY-PCT	MY	PCT	PI-2019003492	19 Dec 2017
200585-NG-PCT	NG	PCT	NG/PT/C/2019/3790	19 Dec 2017
200585-NI-PCT	NI	PCT	2019-000062	19 Dec 2017
200585-NZ-PCT	NZ	PCT	755222	19 Dec 2017
200585-PA-PCT	PA	PCT	2019-15339	19 Dec 2017
200585-PE-PCT	PE	PCT	1276-2019	19 Dec 2017
200585-PH-PCT	PH	PCT	1-2019-501350	19 Dec 2017
200585-PK-NP	PK	NP	664/2017	19 Dec 2017
200585-SG-PCT	SG	PCT	11201905228R	19 Dec 2017
200585-SV-PCT	SV	PCT	2019005923	19 Dec 2017
200585-TH-PCT	TH	PCT	1901003706	19 Dec 2017
200585-TT-PCT	TT	PCT	TT/A/2019/00058	19 Dec 2017
200585-TW-NP	TW	NP	106144799	19 Dec 2017
200585-UA-PCT	UA	PCT	A 2019 07754	19 Dec 2017
200585-US-CNT	US	CNT	16/526,219	30 Jul 2019
200585-US-NP	US	NP	15/846,679 (10/407,44)	19 Dec 2017
200585-VE-NP	VE	NP	2017-000473	19 Dec 2017
200585-VN-PCT	VN	PCT	1-2019-03875	19 Dec 2017
200585-WO-PCT	WO	PCT	PCT/EP2017/083625	19 Dec 2017
200585-ZA-PCT	ZA	PCT	2019/04695	19 Dec 2017

Priority Applications

AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
200585-US-PSP	USA	Provisional	62/436619	20 Dec 2016